FDA 483 - Bioreliance Corporation

The FDA inspected BioReliance Corporation, a non-clinical laboratory in Rockville, MD, from August 6-8, 2019. The inspection revealed several deficiencies related to personnel training, responsibility assignment, material retention, and quality assurance unit oversight. These observations indicate a need for improved controls in the firm's operations.